Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

• Published in: Antimicrobial Agents and Chemotherapy Vol. 56; no. 6; pp. 3086 - 3091
• Main Authors: Miller, Benjamin, Hershberger, Ellie, Benziger, David, Trinh, MyMy, Friedland, Ian
• Format: Journal Article
• Language: English
• Published: Washington, DC American Society for Microbiology 01.06.2012
• Subjects: administration & dosage; Administration, Oral; Adult; adults; adverse effects; Aged; analogs & derivatives; Anti-Bacterial Agents; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Antibiotics. Antiinfectious agents. Antiparasitic agents; beta -Lactamase; Biological and medical sciences; Cephalosporins; Cephalosporins - administration & dosage; Cephalosporins - adverse effects; Cephalosporins - pharmacology; Clinical Therapeutics; combination drug therapy; cross-over studies; dose response; Dose-Response Relationship, Drug; enzyme inhibitors; Female; Half-Life; Humans; Intravenous administration; intravenous injection; Male; Medical sciences; Middle Aged; Penicillanic Acid; Penicillanic Acid - administration & dosage; Penicillanic Acid - adverse effects; Penicillanic Acid - analogs & derivatives; Penicillanic Acid - pharmacokinetics; Pharmacokinetics; pharmacology; Pharmacology. Drug treatments; Tazobactam; Toxicity; Young Adult; Human; Intravenous administration; Healthy subject; Enzyme; Toxicity; Enzyme inhibitor; β-Lactamase; Multiple dose; Tazobactam; Hydrolases; Adult; Safety; Pharmacokinetics

The pharmacokinetics and safety of ceftolozane, a novel cephalosporin, and tazobactam, a β-lactamase inhibitor, alone and in combination as a 2:1 ratio in single doses of up to 2,000 and 1,000 mg of ceftolozane and tazobactam, respectively, and multiple doses of up to 3,000 and 1,500 mg of ceftoloza...